Skip to main content
ABIVAX logo

ABIVAX — Investor Relations & Filings

Ticker · ABVX ISIN · FR0012333284 LEI · 969500D8TMNB184OJU95 PA Manufacturing
Open in API
Filings indexed 873 across all filing types
Latest filing 2017-04-04 Legal Proceedings Report
Country FR France
Listing PA ABVX

About ABIVAX

https://www.abivax.com

Abivax is a clinical-stage biotechnology company developing therapeutics for chronic inflammatory diseases by regulating the immune system. The company's scientific approach is centered on harnessing microRNA (miRNA) biology. Its lead drug candidate, obefazimod, is an investigational, once-daily, oral small molecule with a novel mechanism of action that enhances the expression of miR-124, a natural regulator of the inflammatory response. The primary development program for obefazimod focuses on ulcerative colitis, for which the company has reported positive Phase 3 clinical trial results. Abivax is also investigating the candidate for the treatment of Crohn's disease and other inflammatory conditions, while exploring follow-on compounds.

Recent filings

Filing Released Lang Actions
ABIVAX startet klinische Studie (ABX464-005) zur Evaluierung der Wirkung von ABX464 auf das HIV-Reservoir bei HIV-Patienten
Legal Proceedings Report Classification · 1% confidence The document is a press release dated April 4, 2017, announcing the start of a new clinical study (ABX464-005) for the drug ABX464 concerning HIV treatment. It details the study's objectives, patient enrollment, expected results timeline (Q3 2017), and includes quotes from company executives and medical advisors. This type of announcement, focusing on operational updates, clinical trial progress, and key scientific milestones, is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a specific operational update rather than a summary of overall financial performance (ER) or a mandatory regulatory filing like a 10-K, and it is not merely announcing the publication of a separate report (RPA), the most appropriate general category for a significant, non-financial operational announcement distributed via a news service (DGAP) is Regulatory Filings (RNS). However, given the content is a detailed operational update about a clinical trial, it often falls under the broader umbrella of investor communications that aren't strictly financial results or mandatory SEC forms. Since there is no specific code for 'Clinical Trial Update', RNS serves as the best fit for a general regulatory news announcement distributed via DGAP.
2017-04-04 German
Communicated under the obligation to provide permanent information / Activity of the issuer (acquisition, sale, partnerships, etc.)
Regulatory Filings Classification · 1% confidence The document is a press release dated April 4th, 2017, announcing that ABIVAX has enrolled the first patient in a new clinical trial (ABX464-005) to evaluate the effect of ABX464 on HIV-reservoirs. It details the study design, objectives, expected initial results (Q3 2017), and includes quotes from management and advisors. This content is characteristic of an announcement regarding ongoing research and development activities, often released to the public and investors. It is not a formal regulatory filing like a 10-K, an earnings release (ER), a full transcript (CT), or a formal report (AR, IR). Since it is a specific announcement about a clinical trial initiation and progress, it best fits the general category of Investor Information or a Regulatory Filing (RNS) if no other specific category applies. Given the context of clinical trial updates, which are crucial for investors but don't fit neatly into financial reports or management changes, RNS (Regulatory Filings/General Announcement) is the most appropriate fallback, although it strongly resembles an Investor Presentation (IP) in spirit, it lacks the typical slide deck structure. However, since it is a news announcement about R&D progress, RNS serves as the best fit among the provided options for a general corporate update that isn't a financial report or management change.
2017-04-04 English
Communiqués au titre de l'obligation d'information permanente / Activité de l'émetteur (acquisitions, cessions, partenariats, …)
Regulatory Filings Classification · 1% confidence The document is a press release dated April 4, 2017, announcing the recruitment of the first patient for a new clinical study (ABX464-005) concerning the HIV drug ABX464. It details the study's objectives, methodology (biopsies, patient groups), expected preliminary results timeline (Q3 2017), and includes quotes from medical personnel. It also mentions the status of another ongoing study (ABX464-004) and provides company background. This content is characteristic of an announcement regarding ongoing clinical development and research progress, which falls under general corporate or investor news, but specifically relates to the progression of a drug candidate. Since it is not a formal regulatory filing like a 10-K, an earnings release (ER), or a formal management discussion (MDA), and it is not a presentation (IP) or a transcript (CT), the most appropriate category for a detailed announcement about clinical trial progress and scientific findings, especially when it's a press release format, is often classified as a general Regulatory Filing (RNS) if no other specific category fits perfectly, or sometimes as an Investor Presentation (IP) if it were structured as slides, or a Capital/Financing Update (CAP) if it were about funding. However, given the focus on clinical trial initiation and scientific updates, and lacking a specific 'Clinical Trial Update' code, it functions as a significant corporate announcement. In the context of the provided definitions, this is a specific corporate update that doesn't fit the core definitions of ER, 10-K, or MDA. It is a detailed announcement of a corporate/scientific event. Since it is not a report itself but an announcement, and it doesn't fit the other specific categories well (like DIRS, DIV, NAV), it defaults best to RNS (Regulatory Filings / General Announcement) or potentially IP if viewed as an investor briefing document, but RNS is the safest fallback for non-standard, material announcements.
2017-04-04 French
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Capital/Financing Update Classification · 1% confidence The document is a short press release dated April 3, 2017, confirming ABIVAX's eligibility for the PEA-PME investment scheme based on specific financial and employee criteria defined by French law (Decree n° 2016-1664). This type of announcement, which relates to regulatory status or specific financial/tax incentives rather than core financial results (ER, IR, 10-K) or management changes (MANG), fits best under the general 'Regulatory Filings' category (RNS) as it is a formal regulatory update/confirmation. It is too specific for a general 'Capital/Financing Update' (CAP) as it is about eligibility status, not a fundraising event itself. Given its nature as a formal, brief regulatory confirmation, RNS is the most appropriate fallback.
2017-04-03 French
ABIVAX: Bericht uber die Ergebnisse und den operativen Fortschritt im Geschaftsjahr 2016
Earnings Release Classification · 1% confidence The document is titled "ABIVAX: Bericht über die Ergebnisse und den operativen Fortschritt im Geschäftsjahr 2016" (Report on the results and operational progress for the fiscal year 2016). It contains detailed financial figures for the year ended December 31, 2016, including an income statement comparison with 2015, operational highlights, and a review of R&D progress. The text explicitly states it is publishing its 'Finanzergebnisse für das zum 31. Dezember endende Geschäftsjahr 2016' (financial results for the fiscal year ending December 31, 2016). Although it is presented as a news release/report summary, the comprehensive nature covering the full fiscal year's results and operations strongly aligns with the content of an Annual Report, even if it's not explicitly labeled '10-K' (which is the SEC filing equivalent). Given the options, '10-K' is the closest fit for a comprehensive annual financial and operational report, although 'AR' (Audit Report/Information) could also be considered if the focus was purely on the audited statements. However, the inclusion of operational progress, strategy review, and full-year financials points towards the comprehensive annual reporting structure, making '10-K' the most appropriate classification for a full-year performance review document. FY 2016
2017-03-15 German
Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 1% confidence The document title is "Publication du nombre d'actions composant le capital social et du nombre total de droits de vote" (Publication of the number of shares comprising the share capital and the total number of voting rights). It explicitly references French regulatory articles (Code de commerce and AMF regulations) and provides a table detailing the number of shares and voting rights as of a specific date (28/02/2017). This content directly relates to reporting changes in share structure and voting power, which falls under the category of Major Shareholding Notification (MRQ) or potentially a specific regulatory filing. However, given the specific nature of reporting total voting rights and share count, it aligns most closely with notifications related to significant share ownership changes or capital structure reporting. Since there is no specific code for 'Total Voting Rights Publication', and it is a formal regulatory disclosure about share capital structure, it is best classified as a Major Shareholding Notification (MRQ) or potentially a general Regulatory Filing (RNS). Given the context of reporting share counts and voting rights, MRQ is the most specific fit among the options, as these reports are often triggered by crossing thresholds or are required periodically to maintain transparency on ownership structure. The document is a direct disclosure, not an announcement of another report, and its length (3050 chars) suggests it is the primary document.
2017-03-13 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.